- Home
- SCYX vs VRAR Comparison
SCYX vs VRAR Comparison
Compare SCYX & VRAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- VRAR
- Stock Information
- Founded
- SCYX 1999
- VRAR 2016
- Country
- SCYX United States
- VRAR United States
- Employees
- SCYX N/A
- VRAR N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- VRAR Retail: Computer Software & Peripheral Equipment
- Sector
- SCYX Health Care
- VRAR Technology
- Exchange
- SCYX Nasdaq
- VRAR Nasdaq
- Market Cap
- SCYX 28.5M
- VRAR 33.3M
- IPO Year
- SCYX 2014
- VRAR 2021
- Fundamental
- Price
- SCYX $0.82
- VRAR $1.67
- Analyst Decision
- SCYX
- VRAR Strong Buy
- Analyst Count
- SCYX 0
- VRAR 1
- Target Price
- SCYX N/A
- VRAR $2.62
- AVG Volume (30 Days)
- SCYX 176.2K
- VRAR 146.9K
- Earning Date
- SCYX 08-07-2025
- VRAR 05-15-2025
- Dividend Yield
- SCYX N/A
- VRAR N/A
- EPS Growth
- SCYX N/A
- VRAR N/A
- EPS
- SCYX N/A
- VRAR N/A
- Revenue
- SCYX $2,630,000.00
- VRAR $8,756,789.00
- Revenue This Year
- SCYX $463.61
- VRAR $23.96
- Revenue Next Year
- SCYX $310.80
- VRAR $12.15
- P/E Ratio
- SCYX N/A
- VRAR N/A
- Revenue Growth
- SCYX N/A
- VRAR N/A
- 52 Week Low
- SCYX $0.66
- VRAR $0.50
- 52 Week High
- SCYX $2.29
- VRAR $7.00
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- VRAR 66.01
- Support Level
- SCYX $0.67
- VRAR $1.31
- Resistance Level
- SCYX $0.75
- VRAR $1.38
- Average True Range (ATR)
- SCYX 0.04
- VRAR 0.13
- MACD
- SCYX 0.01
- VRAR 0.03
- Stochastic Oscillator
- SCYX 93.53
- VRAR 80.70
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.